483 related articles for article (PubMed ID: 29491151)
1. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
J Virol; 2018 May; 92(9):. PubMed ID: 29491151
[TBL] [Abstract][Full Text] [Related]
2. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
4. Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.
Painter SL; Biek R; Holley DC; Poss M
J Virol; 2003 Aug; 77(15):8448-61. PubMed ID: 12857914
[TBL] [Abstract][Full Text] [Related]
5. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.
Parrish NF; Wilen CB; Banks LB; Iyer SS; Pfaff JM; Salazar-Gonzalez JF; Salazar MG; Decker JM; Parrish EH; Berg A; Hopper J; Hora B; Kumar A; Mahlokozera T; Yuan S; Coleman C; Vermeulen M; Ding H; Ochsenbauer C; Tilton JC; Permar SR; Kappes JC; Betts MR; Busch MP; Gao F; Montefiori D; Haynes BF; Shaw GM; Hahn BH; Doms RW
PLoS Pathog; 2012; 8(5):e1002686. PubMed ID: 22693444
[TBL] [Abstract][Full Text] [Related]
6. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
7. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.
Bouvin-Pley M; Beretta M; Moreau A; Roch E; Essat A; Goujard C; Chaix ML; Moiré N; Martin L; Meyer L; Barin F; Braibant M
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567994
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic Correlates of HIV-1 Macrophage Tropism.
Arrildt KT; LaBranche CC; Joseph SB; Dukhovlinova EN; Graham WD; Ping LH; Schnell G; Sturdevant CB; Kincer LP; Mallewa M; Heyderman RS; Rie AV; Cohen MS; Spudich S; Price RW; Montefiori DC; Swanstrom R
J Virol; 2015 Nov; 89(22):11294-311. PubMed ID: 26339058
[TBL] [Abstract][Full Text] [Related]
10. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker LG; Hoelscher M; Maboko L; Makhema J; Robb ML; Abdool Karim S; Abdool Karim Q; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
PLoS Pathog; 2016 Jul; 12(7):e1005742. PubMed ID: 27434311
[TBL] [Abstract][Full Text] [Related]
11. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
12. Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties.
Thenin S; Samleerat T; Tavernier E; Ngo-Giang-Huong N; Jourdain G; Lallemant M; Barin F; Braibant M
Virology; 2012 Apr; 426(1):12-21. PubMed ID: 22310702
[TBL] [Abstract][Full Text] [Related]
13. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
15. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
16. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
18. Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.
Martinez DR; Tu JJ; Kumar A; Mangold JF; Mangan RJ; Goswami R; Giorgi EE; Chen J; Mengual M; Douglas AO; Heimsath H; Saunders KO; Nicely NI; Eudailey J; Hernandez G; Morgan-Asiedu PK; Wiehe K; Haynes BF; Moody MA; LaBranche C; Montefiori DC; Gao F; Permar SR
mBio; 2020 Mar; 11(2):. PubMed ID: 32156815
[TBL] [Abstract][Full Text] [Related]
19. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
20. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
O'Rourke SM; Sutthent R; Phung P; Mesa KA; Frigon NL; To B; Horthongkham N; Limoli K; Wrin T; Berman PW
PLoS One; 2015; 10(3):e0119608. PubMed ID: 25793890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
